Immunome Appoints Sandra Swain and Revises Audit Committee

An announcement from Immunome (IMNM) is now available.

Immunome, Inc. has appointed Sandra Swain, M.D. as a Class III director and member of the Audit Committee, with her term ending at the 2026 annual stockholders’ meeting. Dr. Swain’s selection was independent of any other agreements, and she’ll receive standard compensation, including cash retainers and stock options that vest over time, with provisions for accelerated vesting in case of a company takeover. Isaac Barchas has stepped down from the Audit Committee, which now includes Carol Schafer, Dr. Swain, and Jean-Jacques Bienaimé.

For an in-depth examination of IMNM stock, go to TipRanks’ Stock Analysis page.